SENS vs DXCM Stock Comparison: AI Score, Valuation, Performance and Upside
Senseonics and DexCom both compete in continuous glucose monitoring, but DexCom is the established wearable sensor market leader with far greater scale, while Senseonics offers a niche implantable alternative dependent on a commercial partnership for distribution reach.
SENS offers a speculative bet on a differentiated implantable CGM technology reaching wider adoption, while DXCM offers exposure to the established, scaled wearable CGM leader. The choice comes down to risk tolerance for a smaller niche player versus a proven market leader.
DXCM holds the edge across 4 of 5 key metrics in this comparison. DXCM leads on both 1-year return (+14.87%) and forward P/E quality (29.07x vs -4.95x for SENS), a relatively favorable combination of momentum and valuation. On fundamentals, SENS is growing revenue faster (117.80%), while DXCM maintains the higher operating margin (24.33%) — a classic growth-versus-profitability split. Analyst consensus implies meaningfully more upside for SENS (+39.15%) than for DXCM (+3.63%).
Human Wall Street analysts' price targets, typically implying a ~12-month view — a separate signal from this site's own AI Prediction Signal further down the page, which is a 5-/30-day machine-learning forecast based on price history alone.
- Want speculative exposure to a differentiated implantable CGM technology
- Believe extended-wear implantable sensors can carve out a lasting niche among certain patients
- Are comfortable with the higher risk profile of a smaller, partnership-dependent medtech company
- See global diabetes prevalence trends as a long-term tailwind for CGM adoption broadly
- Prefer the established leader in wearable continuous glucose monitoring technology
- Value a broader addressable market spanning intensive insulin users and beyond
- Want exposure to CGM growth without the concentration risk of a single niche product
- Believe continued sensor innovation will sustain DexCom's competitive position
| Metric | SENS | DXCM |
|---|---|---|
| AI scorei | 26.1 | 52.1 |
| AI ranki | #2644 | #414 |
| Latest closei | $9.37 | $87.93 |
| 1M returni | +2.85% | -1.86% |
| 6M returni | +44.60% | +30.71% |
| 1Y returni | +2.97% | +14.87% |
How much would $10,000 be worth today if invested at the start of each period, with all dividends reinvested?
| Period | SENS | DXCM |
|---|---|---|
| 1Y ago | $10.3K (+3.0%) started 2025-09-18 | $11.5K (+15.0%) started 2025-09-17 |
| 5Y ago | $1.35K (-86.5%) started 2021-09-20 | $6.31K (-36.9%) started 2021-09-20 |
| 10Y ago | $1.17K (-88.3%) started 2016-09-19 | $37.79K (+277.9%) started 2016-09-19 |
Hypothetical — past performance does not guarantee future results.
| Metric | SENS | DXCM |
|---|---|---|
| Market capi | $509.18M | $34.27B |
| Trailing P/Ei | N/A | 35.90 |
| Forward P/Ei | -4.95 | 29.07 |
| Price/Salesi | N/A | 8.19 |
| EV/Revenuei | 8.84 | 6.79 |
| Analyst targeti | $13.40 | $94.12 |
| Target upsidei | +39.15% | +3.63% |
| Metric | SENS | DXCM |
|---|---|---|
| Revenue growthi | 117.80% | 13.10% |
| Earnings growthi | N/A | 43.60% |
| EPS growthi | N/A | +43.60% |
| FCF margini | -122.03% | +20.55% |
| Operating margini | -248.48% | 24.33% |
| Profit margini | -225.34% | 20.12% |
| ROIC proxyi | -118.24% | 38.49% |
| Return on equityi | -118.24% | 38.49% |
| Dividend yieldi | N/A | N/A |
| Payout ratioi | 0.00% | 0.00% |
| Dividend growth streaki | N/A | N/A |
| Betai | 1.08 | 1.41 |
| Debt/equityi | 69.56 | 53.35 |
| Current ratioi | 6.75 | 1.73 |
| Quick ratioi | 6.22 | 1.37 |
Over the past year, SENS and DXCM have moved weakly in the same direction (correlation of 0.17), based on daily returns.
Lower drawdown and smaller single-period drops generally indicate a smoother ride, though they do not guarantee lower future risk.
| Period | Metric | SENS | DXCM |
|---|---|---|---|
| 1Y | Growthi | +2.97% | +15.03% |
| CAGRi | +2.97% | +15.05% | |
| Volatilityi | 83.86% | 41.19% | |
| Sharpe ratioi | 0.39 | 0.44 | |
| Sortino ratioi | 0.60 | 0.63 | |
| Max drawdowni | 56.99% | 28.26% | |
| Current drawdowni | 17.08% | 4.78% | |
| Avg drawdowni | 37.56% | 10.65% | |
| Ulcer Indexi | 39.83% | 12.52% | |
| Max daily dropi | 22.84% | 14.63% | |
| Max wkly dropi | 31.09% | 17.22% | |
| 5Y | Growthi | -86.46% | -36.94% |
| CAGRi | -32.99% | -8.82% | |
| Volatilityi | 90.38% | 47.34% | |
| Sharpe ratioi | -0.07 | -0.04 | |
| Sortino ratioi | -0.11 | -0.06 | |
| Max drawdowni | 93.79% | 66.32% | |
| Current drawdowni | 88.02% | 45.99% | |
| Avg drawdowni | 76.87% | 40.59% | |
| Ulcer Indexi | 79.58% | 43.57% | |
| Max daily dropi | 33.70% | 40.66% | |
| Max wkly dropi | 48.49% | 42.68% | |
| 10Y | Growthi | -88.29% | +277.95% |
| CAGRi | -19.31% | +14.23% | |
| Volatilityi | 93.51% | 48.75% | |
| Sharpe ratioi | 0.15 | 0.43 | |
| Sortino ratioi | 0.26 | 0.62 | |
| Max drawdowni | 95.39% | 66.32% | |
| Current drawdowni | 91.11% | 45.99% | |
| Avg drawdowni | 67.13% | 27.99% | |
| Ulcer Indexi | 72.20% | 33.86% | |
| Max daily dropi | 33.70% | 40.66% | |
| Max wkly dropi | 48.49% | 42.68% |
| Category | SENS | DXCM |
|---|---|---|
| Company | Senseonics Holdings, Inc. | DexCom, Inc. |
| Sector | Healthcare | Healthcare |
| Industry | Medical Devices | Medical Devices |
| Core business | A medical technology company that develops implantable continuous glucose monitoring systems, offering an under-the-skin sensor approach as an alternative to adhesive wearable sensors for diabetes management. | A medical device company that designs and markets wearable continuous glucose monitoring systems used by people with diabetes to track glucose levels in real time without routine fingerstick testing. |
| Investor focus | Commercial partnership execution, sensor longevity improvements, and adoption rates among patients seeking an alternative to daily-wear sensor patches. | New sensor generation adoption, expansion into non-intensive insulin users and broader consumer health markets, and international growth. |
- Implantable sensor design offers a differentiated form factor that appeals to patients who dislike adhesive wearable sensors
- Extended sensor wear duration compared to some wearable alternatives can reduce the frequency of sensor changes for users
- Strategic commercialization partnership provides access to broader sales and distribution infrastructure than the company could build alone
- Established market leadership in wearable CGM technology provides brand recognition and physician trust built over many product generations
- Simple self-applied wearable design lowers the adoption barrier relative to implantable alternatives
- Expanding addressable market beyond intensive insulin users into broader diabetes and wellness segments supports a longer growth runway
- Small revenue base relative to larger CGM competitors leaves the company more exposed to shifts in partner strategy or funding needs
- Implantation procedure requirement creates a higher barrier to adoption compared to simple self-applied wearable sensors
- Competitive pressure from larger, well-capitalized CGM makers continues to intensify across the diabetes technology market
- Intensifying competition from other wearable CGM makers pressures pricing and market share over time
- Reliance on continued innovation to maintain differentiation as sensor technology matures across the industry
- Reimbursement policy changes from insurers and government payers can affect the pace of new patient adoption
Want deeper AI forecasts?
This comparison page is public and free forever. Subscribers can unlock saved watchlists, full AI rankings, detailed forecasts, and interactive analysis tools.
Full valuation workup with AI Score, Monte Carlo forecast, and bull/bear case — free preview, premium data from $3.99.